Date: 2016-01-08
Type of information: Development agreement
Compound:
Company: Moderna Therapeutics (USA - MA) Pharmaceutical Product Development (PPD) (USA - NC)
Therapeutic area: Technology - Services
Type agreement: development
Action mechanism:
Disease:
Details: * On January 8, 2016, Moderna Therapeutics and Pharmaceutical Product Development (PPD) announced a strategic collaboration to support Moderna’s evolution as a clinical-stage company. Under the terms of the agreement, PPD will play a significant role in Moderna’s clinical development efforts, including support for investigational new drug (IND) strategic planning, as well as for clinical trial design and execution. The collaboration is built around a unique risk-sharing model that incentivizes both organizations to achieve shared milestones. Moderna’s pipeline is composed of a series of novel drug modalities, each representing a distinct application of the company’s proprietary core expression mRNA platform to encode proteins that achieve a therapeutic benefit. Moderna’s current modalities include infectious disease vaccines, personalized cancer vaccines, intracellular/transmembrane liver proteins, intratumoral cancer therapy, and secreted antibodies and proteins. Moderna is leveraging these modalities to advance drugs across a broad spectrum of therapeutic areas via its four ventures, including Valera, focused on infectious diseases; Elpidera, focused on rare diseases; Onkaido, focused on oncology; and Caperna, focused on personalized cancer vaccines.
Financial terms:
Latest news:
